Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 14:17:17562848231222344.
doi: 10.1177/17562848231222344. eCollection 2024.

Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis

Eduard Brunet-Mas  1   2 , Belen Garcia-Sagué  1 , Emli Vela  3 , Luigi Melcarne  1 , Laura Patricia Llovet  1 , Caridad Pontes  4   5 , Pilar García-Iglesias  1 , Anna Puy  1 , Sergio Lario  1   2 , Maria Jose Ramirez-Lazaro  1   2 , Albert Villoria  6   2 , Johan Burisch  7   8 , Gilaad G Kaplan  9 , Xavier Calvet  6   2   10
Affiliations

Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis

Eduard Brunet-Mas et al. Therap Adv Gastroenterol. .

Abstract

Background: Inflammatory bowel disease (IBD) has a major economic impact on healthcare costs.

Objectives: The aim of this study was to evaluate the current healthcare expenditure associated with IBD in a population-wide study in Catalonia.

Design: Retrospective observational study.

Methods: All patients with IBD included in the Catalan Health Surveillance System (CHSS) were considered eligible. The CHSS compiles data on more than 7 million individuals in 2020 (34,823 with IBD). Data on the use of healthcare resources and its economic impact were extracted applying the International Classification of Diseases, 10th revision, Clinical Modification codes (ICD-10-CM codes). Health expenditure, comorbidities, and hospitalization were calculated according to the standard costs of each service provided by the Department of Health of the Catalan government. The data on the IBD population were compared with non-IBD population adjusted for age, sex, and income level. IBD costs were recorded separately for Crohn's disease (CD) and ulcerative colitis (UC).

Results: Prevalence of comorbidities was higher in patients with IBD than in those without. The risk of hospitalization was twice as high in the IBD population. The overall healthcare expenditure on IBD patients amounted to 164M€. The pharmacy cost represents the 60%. The average annual per capita expenditure on IBD patients was more than 3.4-fold higher (IBD 4200€, non-IBD 1200€). Average costs of UC were 3400€ and 5700€ for CD.

Conclusion: The risk of comorbidities was twice as high in patients with IBD and their use of healthcare resources was also higher than that of their non-IBD counterparts. Per capita healthcare expenditure was approximately 3.4 times higher in the population with IBD.

Trial registration: The study was not previously registered.

Keywords: Catalonia; economy; inflammatory bowel disease.

Plain language summary

Economic impact of inflammatory bowel disease in Catalonia The manuscript includes data of the most recent epidemiologic data about the high economic impact of IBD in Catalonia.

PubMed Disclaimer

Conflict of interest statement

AV has served as a speaker and consultant from for MSD and Abbvie. EB-M has served as a speaker and consultant for Janssen and Chiesi. LM has served as a speaker and consultant from for MSD, Abbvie, Janssen, Takeda, Pfizer, and Tillots. BG-S, EV, LPL, CP, PG-I, AP, SL, and MJR-L have no conflicts of interest to declare. JB reports personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos. GGK has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, Amgen, and Takeda. He has received research support from Ferring, Janssen, Abbvie, GlaxoSmithKline, Merck, and Shire. He has been a consultant for Gilead. He shares ownership of a patent: Treatment of Inflammatory Disorders, Autoimmune Disease, and PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 September 2018. XC has received grants for research from Abbott, MSD, and Vifor, and fees for advisory board services from Abbott, MSD, Takeda, and Vifor. He has also given lectures for Abbott, MSD, Takeda, Shire, and Allergan.

Figures

Figure 1.
Figure 1.
Healthcare expenditure distribution of IBD; CD and UC in 2020. CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
Figure 2.
Figure 2.
Healthcare resource distribution of IBD; CD and UC in 2020. CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
See this image and copyright information in PMC

References

    1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–2078. - PMC - PubMed
    1. Burisch J, Jess T, Martinato M, et al.. The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis 2013; 7: 322–337. - PubMed
    1. Ng SC, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778. - PubMed
    1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012; 380: 1590–1605. - PubMed
    1. Golovics PA, Mandel MD, Lovasz BD, et al.. Inflammatory bowel disease course in Crohn’s disease: is the natural history changing? World J Gastroenterol 2014; 20: 3198–3207. - PMC - PubMed